anmelden
Sartorius Stedim Biotech releases Universal Registration Document 2025
Werte in diesem Artikel
|
Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Werbung
Aubagne, France | February 16, 2026
Sartorius Stedim Biotech releases Universal Registration Document 2025 Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2025 including the Annual Financial Report. The document is available at the following link: https://www.sartorius.com/urd2025 Financial calendar March 24, 2026 | Annual Shareholders' Meeting April 23, 2026 | Publication of the first quarter results for January to March 2026 July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros, according to preliminary figures. Currently, more than 10,200 employees are working for customers around the globe. Visit our newsroom and follow us on LinkedIn. Contact Verena Sattel External Communications +49 551 308 9261 verena.sattel@sartorius.com Attachment File: Sartorius Stedim Biotech releases Universal Registration Document 2025 | Media Release
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2275078 |
| End of Announcement - EQS News Service | |
|
|
2275078 16-Feb-2026 CET/CEST
Ausgewählte Hebelprodukte auf Sartorius Stedim Biotech
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sartorius Stedim Biotech
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Sartorius Stedim Biotech Aktie News
Sartorius Stedim Biotech Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sartorius Stedim Biotech nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 20.08.26 | Sartorius Stedim Biotech Buy | UBS AG | |
| 12.08.26 | Sartorius Stedim Biotech Outperform | RBC Capital Markets | |
| 28.07.26 | Sartorius Stedim Biotech Outperform | Bernstein Research | |
| 24.07.26 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 23.07.26 | Sartorius Stedim Biotech Outperform | RBC Capital Markets |
